Abstract:

Objective To investigate the effect of intraperitoneal chemotherapy with lobaplatin on liver function in patients with primary liver cancer after operation. Method 92 patients with primary liver cancer admitted to our hospital from July 2021 to February 2022 were randomly into the control group (n=46) and the observation group (n=46), the observation group was given intraperitoneal chemotherapy with lobaplatin on the basis of the control group. All patients were followed up for 6 months. The levels of serum alpha-fetoprotein (AFP), alanine aminotransferase (ALT), aspartate transaminase (AST), total bilirubin (TBIL) were compared between the two groups before operation, 7 days after operation, 1 month and 2 months after operation. Result Two months

after operation, the serum AFP level of patients in the two groups gradually decreased with time, and the serum AFP level in the observation group was lower than that in the control group 7 days, 1 month and 2 months after operation (P ＜ 0.05). Two months after operation, the levels of serum ALT and AST in the two groups were significantly lower than those before operation (P ＜ 0.05); However, there was no significant difference in serum ALT, AST and TBIL levels between the two groups at 7d, 1 month and 2 months after operation (P ＞ 0.05). Within 6 months after operation, the incidence of poor prognosis in the observation group was significantly lower than that in the control group (P＜ 0.05); The mortality rates of the observation group and the control group were 0.00% and 2.17% respectively, with no significant difference (P ＞ 0.05). Conclusion Intraperitoneal chemotherapy with lobaplatin does not significantly increase the risk of liver injury in postoperative patients with primary liver cancer, can improve the prognosis of patients with liver cancer, clinical application of safety, and the survival was good within

6 months.

Key words: Primary liver cancer, Lobaplatin, Perfusion chemotherapy, Liver function